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Positron emission tomography (PET) with [(18)F]fluorode-oxyglucose is increasingly used in early assessment of tumor 
response in non–small-cell lung cancer (NSCLC).1 Circulating 
tumor cells (CTCs) are detectable in patients with NSCLC and 
might provide early indication of response to therapy.2 This 
report describes the role of PET and CTCs in monitoring the 
response to gefitinib in a patient affected by metastatic lung 
adenocarcinoma harboring an activating epidermal growth fac-
tor receptor (EGFR) mutation and with an extremely poor per-
formance status.
CASE REPORT
On November 2010, a 41-year-old man, a former light 
smoker, was admitted to our institution for a right lung nod-
ule with pleural effusion, pericardial effusion, disseminated 
intravascular coagulation, and renal and hepatic failure. The 
Eastern Cooperative Oncology Group performance status 
was 4. PET scan demonstrated tracer accumulation in the 
right lung, pleural, supraclavicular and mediastinic lymph 
nodes, bone and liver (Fig. 1A). The patient  underwent 
 pericardial drainage and started therapy with steroids, diuret-
ics, low–molecular-weight heparin, antithrombin III, and 
fresh frozen plasma. Cytologic evaluation of pericardial 
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FIGURE 1.  Positron 
emission tomography 
scan: (A) at diagnosis; (B ) 
after 3 months of therapy; 
and (C ) after 7 months of 
therapy with gefitinib.
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effusion demonstrated a lung adenocarcinoma. A single slide 
containing 20 stained tumor cells was available for EGFR 
mutational analysis. By using highly sensitive fragment anal-
ysis and polymerase chain reaction/sequencing techniques, it 
was possible to demonstrate in exon 19 of the EGFR gene 
a c.2235–2249 deletion, producing the aminoacidic dele-
tion p.E746-A750. Finally, analysis of 7.5 mL of peripheral 
blood sample with the CellSearch system (Veridex, Raritan, 
NJ) revealed the presence of 32 CTCs, in which the same 
EGFR deletion identified in the primary tumor was detected. 
On December 15, we started therapy with gefitinib 250 mg/
day, with a rapid and dramatic improvement of clinical condi-
tions. After 2 weeks of treatment, the CTC count was 0. The 
PET scan after 3 months of therapy showed only a minimal 
tracer accumulation at the basis of the right lung (standard-
ized uptake value 3.3) (Fig. 1B), and became negative after 
7 months of therapy (Fig. 1C). Response to gefitinib was 
maintained for 11 months, until November 2011, when a 
total body PET/computed tomography scan showed a liver 
progression of disease, whereas CTC count was still negative.
DISCUSSION
Six randomized clinical trials demonstrated the efficacy 
of gefitinib and erlotinib in patients with EGFR-mutation–
positive NSCLC and good performance status (Eastern 
Cooperative Oncology Group 0–1).3 Some reports showed that 
Asian patients with advanced NSCLC and poor performance 
status can be responsive to gefitinib.4 This case confirms the 
possibility of successful treatment in a patient with an EGFR 
mutation and a poor performance status. More importantly, 
our findings highlight the importance of applying highly 
sensitive testing methods to allow the identification of EGFR 
mutations even in samples containing a low number of tumor 
cells, especially in patients who present clinical characteristics 
associated with a high incidence of EGFR mutations. In this 
regard, the assessment of EGFR mutations in CTCs might 
represent an alternative approach in patients for whom samples 
from the primary tumor are not available.5 Finally, this study 
also suggests that both PET analysis and CTC count might 
have a relevant role in monitoring the response to molecular-
targeted agents.
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